ANI's Gout Bet: A Bold Expansion With a Slight Guide Trim

Record revenue and EBITDA, but a key guidance cut and an IQVIA disconnect invite scrutiny.

ANIP · Earnings Call · 2026-08-07

Record Quarter, Mixed Signals

ANI Pharmaceuticals delivered a record second quarter: total net revenues of $266 million, up 26% year-over-year, with Cortrophin Gel at $117.1 million and adjusted EBITDA at $71.6 million. The company reaffirmed its 2026 top-line and EBITDA guidance, but modestly revised Cortrophin revenue down to $520–540 million, a signal that management is tempering expectations even as it invests aggressively in a new gout-focused sales force. As CEO Nikhil Lalwani noted, "“we reported record second quarter 2026 revenues of $266 million for the overall business, record Cortrophin revenues of $117.1 million and record adjusted EBITDA of $71.6 million.” — Nikhil Lalwani, President and Chief Executive Officer · 2026-08-07" The strength is real, but the guidance trim hints at a more nuanced read.

The Gout Expansion: A Bold Bet

The heart of the story is the gout expansion—a 50% increase in rare disease sales representatives to approximately 180, targeting podiatrists and primary care physicians for acute gouty arthritis flares. Management called the early indicators "very positive": “the leading indicators from the gout expansion are very positive” — Nikhil Lalwani, President and Chief Executive Officer · 2026-08-07, with over 95% of new reps already generating multiple new patient cases. Management had signaled this ramp in the prior quarter, with Nikhil noting, "“we have completed that hiring and training, right, for the most part. It will be fully complete by the end of June” — Nikhil Lalwani, President and Chief Executive Officer · 2026-05-08." This is a direct follow-on to the 10-territory pilots that informed the strategy. The investment is intentional: the company expects the full impact to materialize in 2027, with operating leverage arriving after two years of heavy SG&A spend. As Nikhil explained to analysts,

I think the big difference with last year is, we have an expansion that's 3x the previous year's expansion, right? That's fully operational at the end of June.
Nikhil Lalwani, President and Chief Executive Officer · 2026-08-07

The market is watching whether this expansion can translate into the steep Q4 step-up management has embedded in guidance.

The IQVIA Question

A key point of contention is the persistent disconnect between third-party prescription data and ANI's reported revenue. In May, management downplayed the gap; now they explicitly addressed it again. "“Our revised guidance, principally accounts for the actual performance in the first half and largely maintains our expectations for both the existing specialties and the gout expansion in the back half.” — Nikhil Lalwani, President and Chief Executive Officer · 2026-08-07" But the skepticism is founded: the company had previously acknowledged that IQVIA data had been directionally aligned. In the prior call, Nikhil stated, "“IQVIA has been directionally in line with our performance... we can't comment on the recent disconnect.” — Nikhil Lalwani, President and Chief Executive Officer · 2026-05-08" Now they argue the IQVIA data is volatile and have stopped providing direct reconciliation, instead offering internal metrics like "new cases initiated." The market is left to trust management's read on demand momentum.

Financials and the Path to 2027

Underpinning the narrative is strong underlying growth. Total revenue has grown more than 10x over the past decade, and the company generated $115 million in cash from operations in the first half of 2026. Net leverage is a manageable 1x trailing EBITDA, giving it room for M&A—which management flags as a priority for expanding the rare disease franchise. The challenge is that the sales force expansion will compress near-term margins; Q3 EBITDA is guided down sequentially before an expected Q4 rebound. Investors will need to weigh the aggressive investment against the potential for blockbuster gout penetration in 2027. The existing specialties—rheumatology, nephrology, neurology—continue to drive momentum, with July marking the highest month for new cases initiated, but the burden of proof now lies on the gout ramp and on resolving the persistent skepticism around reported revenue versus third-party data.